New hope for rare cancer: targeted pill tested in advanced sarcoma
NCT ID NCT07153887
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests the drug vebreltinib in 30 people with advanced clear cell sarcoma, a rare cancer of the soft tissues. Participants take the drug as a capsule twice daily until the cancer worsens or side effects become too severe. The main goal is to see if the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vebreltinib (a targeted cancer drug taken as a capsule)
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced clear cell sarcoma, a rare and aggressive cancer.
- What could go wrong
- This is a small, early-phase trial with only 30 participants. The drug may not shrink tumors or may cause side effects. Success is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL SARCOMA (CCS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.